期刊文献+

猕猴静脉注射自体RAK细胞剂量安全性研究

Dose Security Experiment of Autologous RAK to Rhesus Monkeys through Intravenous Injection
下载PDF
导出
摘要 目的通过对猕猴静脉注射自体RAK细胞,观察猕猴是否出现血管内细胞栓塞等现象,为评价在人体上回输RAK细胞安全性剂量提供依据。方法随机选择健康雄性猕猴5只,进行自体RAK细胞静脉回输,观察动物在回输过程中及回输结束后14d内动物的生理生化指标是否出现异常,是否出现血管栓塞现象。结果自体RAK细胞回输后至观察期14d结束,5只动物均存活,且精神状态良好,各动物的生理生化指标正常,无行为和体征异常出现。结论猕猴静脉注射自体RAK细胞达到拟用临床剂量上限时不会引起毒性反应,不会引起血管内栓塞现象。 Objective To supply safety dose of reinjection autologous RAK cells to rhesus monkeys through intravenous injection and observe whether embolism will occur. Method Selected five healthy male rhesus monkeys randomly and reinfused autologous RAK cells through intravenous injection. Then observe whether physiological index and biochemical indicator would appear abnormal, and whether embolism would occur during the injection and 14 days since then. Result All the five rhesus monkeys were survived and in good condition3 when the 14 days of observation was over. At the same time, the physiological index, biochemical indicator and physical sign of each monkey was normal, and behavior disorder did not occur among them. Conclusion No toxicity reaction or embolism were happened when rhesus monkeys were injected with upper limited clinical doses of autologous RAK.
出处 《中国比较医学杂志》 CAS 2009年第6期17-20,共4页 Chinese Journal of Comparative Medicine
基金 中日联合基因治疗项目
关键词 自体RAK细胞 猕猴 剂量安全性 Autologous RAK cells Rhesus monkey Dose security
  • 相关文献

参考文献12

  • 1李垮 万云霞 石卫 等.联合重组人纤维连接蛋白活化的杀伤细胞过继性治疗肾癌的实验研究.中华泌尿外科杂志,2007,28(10):656-659.
  • 2李垮,万云霞,石卫,等,自体RAK细胞治疗的体外实验研究[C].第九届全国生物治疗学术会议论文集,2006,165-166.
  • 3万云霞,王铮,李净,等,新型杀伤细胞RAK对人肾癌荷瘤小鼠的治疗作用[C].第九届全国生物治疗学术会议论文集,2006,83-84.
  • 4Mule JJ, Shu S, Schwarz SL, et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin - 2 [J]. Science, 1984,225(4669) : 1487 - 1490.
  • 5Lotze MT, Rosenberg SA. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer[J]. Immunobiology, 1986,172 (3 - 5 ) : 420 - 437.
  • 6Rosenberg SA, Mule JJ. Immunotherapy of cancer with lymphokine- activated killer cells and recombinant interleukin-2 [ J ]. Surgery, 1985,98(3) :437 - 444.
  • 7Curti BD, Longo DL, Ochoa AC. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2 [ J]. J Clin Oncol, 1993,11 (4) : 652 - 660.
  • 8Lum LG, LeFever AV,Treisman JS, et al. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28- costimulated T cells-phase I clinical trial [J]. Immunother, 2001, 24,408 - 419.
  • 9Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltraring human melanomas [ J ]. Immunol, 1989,142 (10) :3714 - 3725.
  • 10Seki N, Hoshino T, Kikuchi M, et al. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer[J]. Cell Immunol, 1997,175(2): 101 - 110.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部